4 citations
,
January 2014 in “RSC Advances” A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
9 citations
,
January 2017 in “Organic Process Research & Development” This article describes the efficient synthesis of (S)-N-(2-bromo-6-methoxypyridin-4-yl)-2-hydroxy-2,4-dimethylpentanamide, a novel topical antiandrogen, with high purity and enantiomeric excess but reports no pharmacological results.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.